uniQure Faces Severe FDA Rebuke Amid Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 7 hours ago
0mins
Should l Buy QURE?
Source: PRnewswire
- FDA Rebuke: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could significantly undermine investor confidence.
- Securities Lawsuit Update: Hagens Berman is updating its investigation into uniQure, urging investors who purchased shares between September 24 and October 31, 2025, to submit Lead Plaintiff applications by the April 13, 2026 deadline, highlighting the urgency of the situation.
- False Statement Allegations: The securities class action alleges that uniQure failed to disclose critical interactions with the FDA and utilized a pivotal study design that was not approved, potentially leading to significant investor losses and legal repercussions.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information about uniQure to assist in the investigation, as the SEC's Whistleblower program offers rewards of up to 30% of any successful recovery, providing an additional layer of protection and incentive for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 16.350
Low
33.00
Averages
49.88
High
70.00
Current: 16.350
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ:QURE) ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants failed to adequately disclose that the design of uniQure's pivotal study for its leading drug candidate in Huntington's Disease was not fully approved by the FDA, resulting in investor losses when the true information was revealed, highlighting a lack of operational transparency.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Advisory: Investors are advised to carefully select qualified counsel, avoiding firms that lack experience and resources, to ensure effective legal representation and support in the class action process.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could significantly undermine investor confidence.
- Securities Lawsuit Update: Hagens Berman is updating its investigation into uniQure, urging investors who purchased shares between September 24 and October 31, 2025, to submit Lead Plaintiff applications by the April 13, 2026 deadline, highlighting the urgency of the situation.
- False Statement Allegations: The securities class action alleges that uniQure failed to disclose critical interactions with the FDA and utilized a pivotal study design that was not approved, potentially leading to significant investor losses and legal repercussions.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information about uniQure to assist in the investigation, as the SEC's Whistleblower program offers rewards of up to 30% of any successful recovery, providing an additional layer of protection and incentive for investors.
See More
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay
- Lawsuit Background: uniQure N.V. is facing a class action lawsuit for failing to disclose the FDA approval delay of its drug AMT-130, with a deadline for lead plaintiff applications set for April 13, 2026, affecting investors who purchased shares between September 24 and October 31, 2025.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, over 49%, from $67.69 on October 31 to $34.29, significantly impacting investors' financial positions due to the FDA's rejection of its clinical trial data.
- Legal Accountability: uniQure and certain executives are charged with failing to disclose material information during the class period, violating federal securities laws, which could lead to severe legal repercussions for the company.
- Investor Rights: Investors wishing to participate in the lawsuit or learn about their legal rights can contact Kahn Swick & Foti LLC for legal support to recover economic losses incurred from the stock price drop.
See More
uniQure Faces Update in Securities Class Action Lawsuit
- FDA Allegations: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Ethical Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially affecting the company's compliance in clinical trials.
- Legal Action: The pending securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, leading to a 49% stock drop on November 3, 2025, reflecting significant failures in information disclosure.
- Critical Deadline: Investors must apply by April 13, 2026, to be appointed as Lead Plaintiff in the class action; failure to act promptly may result in lost opportunities for compensation, further impacting their investment returns.
See More
Notice to Shareholders of uniQure N.V. Regarding Class Action
- Lawsuit Background: The Gross Law Firm has issued a notice to shareholders of uniQure N.V. (NASDAQ:QURE), encouraging those who purchased shares during the class period from September 24, 2025, to October 31, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, uniQure made materially false and/or misleading statements, failing to disclose that the design of its pivotal study was not fully FDA approved and that it might need to delay its Biologics License Application (BLA) timeline for additional studies.
- Participation Requirements: Shareholders must register by April 13, 2026, to participate in the class action, and upon registration, they will receive status updates throughout the lifecycle of the case, ensuring they remain informed about developments.
- Law Firm's Strength: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights and ensuring companies adhere to responsible business practices, seeking recovery for investors who suffered losses due to misleading statements.
See More
uniQure Faces Class Action Lawsuit Amid FDA Criticism
- FDA Allegations: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Class Action Update: Hagens Berman is investigating a securities class action lawsuit against uniQure for failing to disclose critical interactions with the FDA during the class period from September 24 to October 31, 2025, potentially impacting investor decisions.
- Critical Deadline: Investors have until April 13, 2026, to apply as Lead Plaintiff in the class action; failure to act promptly may result in lost claims and exacerbate investor losses, highlighting the urgency of the situation.
- Whistleblower Program: Whistleblowers with non-public information about uniQure can benefit from the SEC Whistleblower program, potentially receiving rewards of up to 30% of any successful recovery, incentivizing insiders to provide crucial information to aid the investigation.
See More
Notice of Class Action Lawsuit for uniQure Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure N.V. (NASDAQ:QURE) ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants failed to adequately disclose that the design of uniQure's pivotal study for its leading drug candidate in Huntington's Disease was not fully approved by the FDA, resulting in investor losses when the true information was revealed, highlighting a lack of operational transparency.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Advisory: Investors are advised to carefully select qualified counsel, avoiding firms that lack experience and resources, to ensure effective legal representation and support in the class action process.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could significantly undermine investor confidence.
- Securities Lawsuit Update: Hagens Berman is updating its investigation into uniQure, urging investors who purchased shares between September 24 and October 31, 2025, to submit Lead Plaintiff applications by the April 13, 2026 deadline, highlighting the urgency of the situation.
- False Statement Allegations: The securities class action alleges that uniQure failed to disclose critical interactions with the FDA and utilized a pivotal study design that was not approved, potentially leading to significant investor losses and legal repercussions.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information about uniQure to assist in the investigation, as the SEC's Whistleblower program offers rewards of up to 30% of any successful recovery, providing an additional layer of protection and incentive for investors.
See More
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay
- Lawsuit Background: uniQure N.V. is facing a class action lawsuit for failing to disclose the FDA approval delay of its drug AMT-130, with a deadline for lead plaintiff applications set for April 13, 2026, affecting investors who purchased shares between September 24 and October 31, 2025.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by $33.40, over 49%, from $67.69 on October 31 to $34.29, significantly impacting investors' financial positions due to the FDA's rejection of its clinical trial data.
- Legal Accountability: uniQure and certain executives are charged with failing to disclose material information during the class period, violating federal securities laws, which could lead to severe legal repercussions for the company.
- Investor Rights: Investors wishing to participate in the lawsuit or learn about their legal rights can contact Kahn Swick & Foti LLC for legal support to recover economic losses incurred from the stock price drop.
See More
uniQure Faces Update in Securities Class Action Lawsuit
- FDA Allegations: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Ethical Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially affecting the company's compliance in clinical trials.
- Legal Action: The pending securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, leading to a 49% stock drop on November 3, 2025, reflecting significant failures in information disclosure.
- Critical Deadline: Investors must apply by April 13, 2026, to be appointed as Lead Plaintiff in the class action; failure to act promptly may result in lost opportunities for compensation, further impacting their investment returns.
See More
Notice to Shareholders of uniQure N.V. Regarding Class Action
- Lawsuit Background: The Gross Law Firm has issued a notice to shareholders of uniQure N.V. (NASDAQ:QURE), encouraging those who purchased shares during the class period from September 24, 2025, to October 31, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, uniQure made materially false and/or misleading statements, failing to disclose that the design of its pivotal study was not fully FDA approved and that it might need to delay its Biologics License Application (BLA) timeline for additional studies.
- Participation Requirements: Shareholders must register by April 13, 2026, to participate in the class action, and upon registration, they will receive status updates throughout the lifecycle of the case, ensuring they remain informed about developments.
- Law Firm's Strength: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights and ensuring companies adhere to responsible business practices, seeking recovery for investors who suffered losses due to misleading statements.
See More
uniQure Faces Class Action Lawsuit Amid FDA Criticism
- FDA Allegations: An FDA official publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Class Action Update: Hagens Berman is investigating a securities class action lawsuit against uniQure for failing to disclose critical interactions with the FDA during the class period from September 24 to October 31, 2025, potentially impacting investor decisions.
- Critical Deadline: Investors have until April 13, 2026, to apply as Lead Plaintiff in the class action; failure to act promptly may result in lost claims and exacerbate investor losses, highlighting the urgency of the situation.
- Whistleblower Program: Whistleblowers with non-public information about uniQure can benefit from the SEC Whistleblower program, potentially receiving rewards of up to 30% of any successful recovery, incentivizing insiders to provide crucial information to aid the investigation.
See More
